Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

MARQIBO KIT

VINCRISTINE SULFATE

Standard Dose
5MG/5ML (1MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview MARQIBO KIT is listed in Drugs@FDA under application 202497 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient VINCRISTINE SULFATE Form and strength INJECTABLE, LIPOSOMAL;INTRAVENOUS - 5MG/5ML (1MG/ML) Sponsor ACROTECH Submission history Latest submission status date: 2022-03-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview MARQIBO KIT is listed in Drugs@FDA under application 202497 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient VINCRISTINE SULFATE Form and strength INJECTABLE, LIPOSOMAL;INTRAVENOUS - 5MG/5ML (1MG/ML) Sponsor ACROTECH Submission history Latest submission status date: 2022-03-15 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
MARQIBO KIT (VINCRISTINE SULFATE) | Drug Monograph | MedicHelpline